RxDoctor Payments Data

Kippy Bodosky

Family · Albion, PANPI 1265950307

Payments from drug & device makers

$10,396in general payments, 2019–2025

Across 657 payments — averaging $15.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$1K
  • Lilly USA, LLC$1K
  • AstraZeneca$621
  • GSK$592
  • Boehringer Ingelheim$490
  • plus $5K from 33 others

What the payments were for

  • Food & beverage$10,396100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,396 in reported general payments places this provider in the 95th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$12,038
Medicare patients
61
Services billed
214

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide15$16,829
XareltoRivaroxaban17$16,468
OzempicSemaglutide17$16,198
EliquisApixaban17$9,837
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$6,099
VascepaIcosapent Ethyl22$5,928
JentaduetoLinagliptin/Metformin Hcl11$5,684
Albuterol Sulfate HfaAlbuterol Sulfate27$1,210
Colchicine13$1,200
Levothyroxine Sodium151$1,101
Lantus SolostarInsulin Glargine,hum.Rec.Anlog14$1,066
Propranolol Hcl ErPropranolol Hcl24$923
SynthroidLevothyroxine Sodium18$827
Omeprazole86$778
Celecoxib26$608

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$1,055$16,82915 claims
Johnson & JohnsonXarelto$120$16,46817 claims
Novo NordiskOzempic$1,508$16,19817 claims
PfizerEliquis$449$9,83717 claims
Boehringer IngelheimJentadueto$490$5,68411 claims
AbbVieSynthroid$1,473$82718 claims
Almatica Pharma LLCSertraline Hcl$16$22340 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,717 family providers in Pennsylvania.

Other family in Albion

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →